NCT03189914View on ClinicalTrials.gov

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

November 21, 2019

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

RX-3117

RX-3117 will be administered orally in combination with Abraxane.

Trial Locations (10)

10065

Rexahn Site, New York

29303

Rexahn Site, Spartanburg

34607

Rexahn Site, Weeki Wachee

40503

Rexahn Site, Lexington

53226

Rexahn Site, Milwaukee

60077

Rexahn Site, Skokie

60435

Rexahn Site, Joliet

85724

Rexahn Site, Tucson

99202

Rexahn Site, Spokane

02115

Rexahn Site, Boston

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT03189914 - RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter